» Articles » PMID: 34974810

DNA Hypermethylation of , and Genes in Oropharyngeal Cancer Associated with Human Papillomavirus

Overview
Journal Epigenetics
Specialty Genetics
Date 2022 Jan 3
PMID 34974810
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Recently, an increasing incidence of HPV-induced oropharyngeal squamous cell carcinoma (OPSCC) has been observed. Moreover, locoregionally advanced stages require a combined modal approach, and the prognosis is poor. Therefore, it is essential to find early diagnostic and prognostic biomarkers. DNA methylation changes play a crucial role in the process of carcinogenesis and are often investigated as promising biomarkers in many types of cancer. For analysis of DNA methylation levels of selected tumour suppressor genes in HPV-positive and HPV-negative samples (including primary tumours and corresponding metastases of metastasizing OPSCCs, primary tumours of non-metastasizing OPSCCs, and control samples), methylation-specific MLPA and methylation-specific high-resolution melting analyses were used. A significant difference in methylation between OPSCCs and the control group was observed in (P < 0.01) and (P < 0.05) genes. and hypermethylation was detected mostly in HPV-positive samples; all but one HPV-negative samples were unmethylated. Moreover, hypermethylation of gene was observed in metastases compared with control samples and was also associated with shorter overall survival of all patients (P < 0.05). Associations described herein between promoter methylation of selected genes and clinicopathological data could benefit OPSCC patients in the future by improvement in screening, early detection, and prognosis of the disease.

Citing Articles

Repression of CADM1 transcription by HPV type 18 is mediated by three-dimensional rearrangement of promoter-enhancer interactions.

Campos-Leon K, Ferguson J, Gunther T, Wood C, Wingett S, Pekel S PLoS Pathog. 2025; 21(1):e1012506.

PMID: 39869645 PMC: 11801731. DOI: 10.1371/journal.ppat.1012506.


Multicohort Epigenome-Wide Association Study of All-Cause Cardiovascular Disease and Cancer Incidence: A Cardio-Oncology Approach.

Domingo-Relloso A, Riffo-Campos A, Zhao N, Ayala G, Haack K, Manterola C JACC CardioOncol. 2024; 6(5):731-742.

PMID: 39479324 PMC: 11520201. DOI: 10.1016/j.jaccao.2024.07.014.


Using Liquid Biopsy to Predict Relapse After Radiotherapy in Squamous Cell Head-Neck and Esophageal Cancer.

Koukourakis I, Xanthopoulou E, Koukourakis M Cancer Diagn Progn. 2023; 3(4):403-410.

PMID: 37405217 PMC: 10316059. DOI: 10.21873/cdp.10232.


Circulating Cell-Free DNA-Based Methylation Pattern in Saliva for Early Diagnosis of Head and Neck Cancer.

Birknerova N, Mancikova V, Paul E, Matyasovsky J, cekan P, Palicka V Cancers (Basel). 2022; 14(19).

PMID: 36230805 PMC: 9563959. DOI: 10.3390/cancers14194882.

References
1.
van Kempen P, van Bockel L, Braunius W, Moelans C, van Olst M, De Jong R . HPV-positive oropharyngeal squamous cell carcinoma is associated with TIMP3 and CADM1 promoter hypermethylation. Cancer Med. 2014; 3(5):1185-96. PMC: 4302669. DOI: 10.1002/cam4.313. View

2.
Guerrero-Preston R, Michailidi C, Marchionni L, Pickering C, Frederick M, Myers J . Key tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer. Epigenetics. 2014; 9(7):1031-46. PMC: 4143405. DOI: 10.4161/epi.29025. View

3.
Overmeer R, Henken F, Snijders P, Claassen-Kramer D, Berkhof J, Helmerhorst T . Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC. J Pathol. 2008; 215(4):388-97. DOI: 10.1002/path.2367. View

4.
Chen K, Wang G, Peng L, Liu S, Fu X, Zhou Y . CADM1/TSLC1 inactivation by promoter hypermethylation is a frequent event in colorectal carcinogenesis and correlates with late stages of the disease. Int J Cancer. 2010; 128(2):266-73. DOI: 10.1002/ijc.25356. View

5.
Fisser M, Rommer A, Steinleitner K, Heller G, Herbst F, Wiese M . Induction of the proapoptotic tumor suppressor gene Cell Adhesion Molecule 1 by chemotherapeutic agents is repressed in therapy resistant acute myeloid leukemia. Mol Carcinog. 2014; 54(12):1815-9. DOI: 10.1002/mc.22252. View